・H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130. ・The firm stated that it has “continued conviction” in AMT-130’s …
QURE stock’s relentless rally continues today — here’s why HC Wainwright is bullish on uniQure
view original post